Published in Int J Mol Sci on December 28, 2016
Celebrating More Than a Century of Research on Antibodies: Affirmation Through Negation via Complex Formation. Pathog Immun (2017) 0.75
Development of Antibody-Drug Conjugates Using DDS and Molecular Imaging. Bioengineering (Basel) (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 83.56
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia (2006) 3.54
Targeting tyrosine kinases in cancer: the second wave. Science (2006) 3.52
Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A (1979) 3.46
Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther (2010) 3.42
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem (2006) 3.24
Nanobodies: natural single-domain antibodies. Annu Rev Biochem (2013) 3.12
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol (2010) 3.06
Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol (2012) 3.03
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol (2007) 2.83
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol (2009) 2.71
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol (2005) 2.55
A novel method of 18F radiolabeling for PET. J Nucl Med (2009) 2.35
Recent developments in PET detector technology. Phys Med Biol (2008) 2.25
PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun (2008) 2.16
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med (2009) 2.12
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol (2012) 1.87
Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist (2007) 1.76
Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med (2010) 1.75
Recent Advances and Future Advances in Time-of-Flight PET. Nucl Instrum Methods Phys Res A (2007) 1.72
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann Oncol (2015) 1.72
In vivo biodistribution and accumulation of 89Zr in mice. Nucl Med Biol (2011) 1.59
Bioorthogonal chemistry: recent progress and future directions. Chem Commun (Camb) (2010) 1.58
Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging (2006) 1.58
64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med (2013) 1.46
Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry. Bioconjug Chem (2011) 1.45
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol (2007) 1.44
PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem (2013) 1.42
Bifunctional chelates for metal nuclides. Q J Nucl Med Mol Imaging (2007) 1.38
The growing impact of bioorthogonal click chemistry on the development of radiopharmaceuticals. J Nucl Med (2013) 1.22
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging (2012) 1.21
Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev (2013) 1.20
Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET. J Nucl Med (2013) 1.14
Immunotherapy of Non-Hodgkin's lymphomas. Hematology Am Soc Hematol Educ Program (2001) 1.12
PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors. J Nucl Med (2010) 1.11
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging (2014) 1.10
Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer. Cancer Res (2015) 1.08
Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. Cancer Res (2015) 1.06
A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res (2003) 1.05
In vivo imaging with antibodies and engineered fragments. Mol Immunol (2015) 0.98
Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging (2015) 0.97
Monoclonal antibodies in human cancer. Drugs Today (Barc) (2003) 0.96
PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol (2012) 0.95
Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients. Med Oncol (2014) 0.94
Immuno-PET of cancer: a revival of antibody imaging. J Nucl Med (2011) 0.94
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma. J Nucl Med (2015) 0.93
The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin Immunol (2011) 0.93
Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes. Bioconjug Chem (2015) 0.92
89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget (2015) 0.91
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials? Front Pharmacol (2016) 0.91
(89)Zr-labeled compounds for PET imaging guided personalized therapy. Drug Discov Today Technol (2011) 0.90
Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy. Am J Nucl Med Mol Imaging (2014) 0.88
Designing the magic bullet? The advancement of immuno-PET into clinical use. J Nucl Med (2013) 0.88
ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate (1998) 0.87
Engineered Fc based antibody domains and fragments as novel scaffolds. Biochim Biophys Acta (2014) 0.87
Everolimus Reduces (89)Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors. J Nucl Med (2014) 0.86
Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer. MAbs (2014) 0.85
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer. Eur J Nucl Med Mol Imaging (2014) 0.83
Mapping biological behaviors by application of longer-lived positron emitting radionuclides. Adv Drug Deliv Rev (2012) 0.83
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET. J Nucl Med (2015) 0.83
Tumor immunotargeting using innovative radionuclides. Int J Mol Sci (2015) 0.82
Pilot study of (89)Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer. EJNMMI Res (2014) 0.82
Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges. Expert Opin Biol Ther (2005) 0.82
Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides. Curr Med Chem (2003) 0.82
ImmunoPET to help stratify patients for targeted therapies and to improve drug development. Eur J Nucl Med Mol Imaging (2016) 0.82
Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients. J Nucl Med (2016) 0.80
Receptor tyrosine kinases and anticancer therapy. Curr Pharm Des (2005) 0.78
18F labeling for immuno-PET: where speed and contrast meet. J Nucl Med (2007) 0.78
Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues. Nucl Med Biol (2010) 0.77
Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. 1978. Biochem Biophys Res Commun (2012) 0.76
Radiopharmaceuticals as probes to characterize tumour tissue. Eur J Nucl Med Mol Imaging (2015) 0.76
Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. Front Med (Lausanne) (2015) 0.76
Enhanced tumor retention of radioiodinated anti-epidermal growth factor receptor antibody using novel bifunctional iodination linker for radioimmunotherapy. Oncol Rep (2016) 0.76